DJIA52064.10 -316.56
S&P 5007591.70 -44.66
NASDAQ26081.72 -171.62
Russell 20002890.95 -30.28
German DAX25361.15 -215.30
FTSE 10010608.92 -61.14
CAC 408116.76 -39.91
EuroStoxx 506269.65 -42.10
Nikkei 22565270.95 128.17
Hang Seng24954.47 -320.49
Shanghai Comp3934.40 -17.11
KOSPI7033.92 -17.72
Bloomberg Comm IDX146.97 1.83
WTI Crude-fut103.85 6.00
Brent Crude-fut103.93 6.85
Natural Gas2.84 0.04
Gasoline-fut3.44 0.22
Gold-fut4358.50 -87.50
Silver-fut64.09 -3.83
Platinum-fut1784.10 -120.30
Palladium-fut1290.50 -79.50
Copper-fut6.53 -0.33
Aluminum-spot3195.00 0.00
Coffee-fut289.95 -1.20
Soybeans-fut1331.75 23.00
Wheat-fut741.50 12.75
Bitcoin77201.01 -796.51
Ethereum USD2459.80 6.84
Litecoin52.35 -0.55
Dogecoin0.08 -0.01
EUR/USD1.1620 -0.0001
USD/JPY153.66 -0.42
GBP/USD1.3554 0.0017
USD/CHF0.8107 0.0010
USD IDX99.08 0.33
US 10-Yr TR4.961 0.121
GER 10-Yr TR3.5025 0.0062
UK 10-Yr TR5.3985 0.0207
JAP 10-Yr TR2.925 0.015
Fed Funds3.75 0
SOFR3.64 0
High-rise commercial buildings

Sub Markets

Topics

Alternative Assets  + Private Equity  | 
Patient Square Forms $300M Company for Medical Device Startups

Patient Square Forms $300M Company for Medical Device Startups

Patient Square Capital, a Menlo Park, CA-based healthcare investment firm, has created and committed $300 million to Elevage Medical Technologies; a new portfolio company intended to support growth in the medical device industry.

Elevage Medical Technologies, which is currently a remote company without a corporate headquarters, will follow a similar strategy of Patient Square’s Enavate Sciences, which made its debut nearly a year ago. Both aim to provide financial support and lend their experience to startups looking to build out their technical and clinical operations.

“This is an exciting time for innovation in the medical device field, and through Elevage Medical Technologies, we will support the growth of new, life-changing technologies to impact patient care,” said newly appointed CEO Evan Melrose.

Melrose most recently served as the founding managing director of healthcare investment firm Spindletop Capital. Before that, he held executive titles at two other venture capital firms – PTV Sciences and Burrill & Company.

Patient Square’s launch comes a few weeks after it closed its debut fund with approximately $3.9 billion, bringing its total assets to roughly $5.9 billion. Its portfolio includes Apollo Therapeutics, hearing aid developer Eargo and gene therapy weaver Kriya Therapeutics.

Connect

Inside The Story

Elevage Medical TechnologiesPatient Square Capital

About Joe Palmisano

Joe Palmisano is editorial director of Connect Money, where he oversees daily coverage of alternative assets, direct investments, financial advisory and the economy. He brings three decades of experience as a financial journalist, analyst and portfolio manager. Before joining Connect Money, Palmisano wrote for The Wall Street Journal, covering foreign exchange, global fixed-income and equity markets. He later served as a senior research analyst and portfolio manager, producing market analysis and managing foreign exchange and U.S. equity portfolios for FX Concepts. His work has also appeared in SFO Magazine and CMT Association publications. Palmisano earned a bachelor’s degree in finance from The American University and holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.